Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2016 | Pages:
334 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016', provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris) - The report reviews pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Plaque Psoriasis (Psoriasis Vulgaris) therapeutics and enlists all their major and minor projects - The report assesses Plaque Psoriasis (Psoriasis Vulgaris) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Plaque Psoriasis (Psoriasis Vulgaris) Overview 11 Therapeutics Development 12 Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Overview 12 Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies 13 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies 22 Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development 28 3SBio Inc. 28 AbGenomics International, Inc. 29 Almirall, S.A. 30 Amgen Inc. 31 AstraZeneca Plc 32 Avexxin AS 33 BIOCAD 34 Biocon Limited 35 Bionovis SA 36 Boehringer Ingelheim GmbH 37 Bristol-Myers Squibb Company 38 Can-Fite BioPharma Ltd. 39 Celgene Corporation 40 Cellceutix Corporation 41 Celltrion, Inc. 42 Clonz Biotech Private Limited 43 Coherus BioSciences, Inc. 44 Delenex Therapeutics AG 45 Eli Lilly and Company 46 Epirus Biopharmaceuticals, Inc. 47 Forward Pharma A/S 48 Galectin Therapeutics, Inc. 49 Genor BioPharma Co., Ltd. 50 GlaxoSmithKline Plc 51 Idera Pharmaceuticals, Inc. 52 Invion Limited 53 Johnson & Johnson 54 Kadmon Corporation, LLC 55 Kineta, Inc. 56 Kyowa Hakko Kirin Co., Ltd. 57 LEO Pharma A/S 58 Lipidor AB 59 Mabion SA 60 Maruho Co., Ltd. 61 Mitsubishi Tanabe Pharma Corporation 62 Momenta Pharmaceuticals, Inc. 63 Mycenax Biotech Inc. 64 Novartis AG 65 Oncobiologics, Inc. 66 Pfizer Inc. 67 Promius Pharma, LLC 68 Protalix BioTherapeutics, Inc. 69 Provectus Biopharmaceuticals, Inc. 70 Sandoz International GmbH 71 Shanghai Celgen Bio-Pharmaceutical Co., Ltd. 72 Sucampo Pharmaceuticals, Inc. 73 Sun Pharma Advanced Research Company Ltd. 74 Takeda Pharmaceutical Company Limited 75 TetraLogic Pharmaceuticals 76 Therapeutic Proteins International, LLC 77 UCB S.A. 78 Valeant Pharmaceuticals International, Inc. 79 XBiotech USA, Inc. 80 Ziarco Pharma Ltd 81 Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment 82 Assessment by Monotherapy Products 82 Assessment by Combination Products 83 Assessment by Target 84 Assessment by Mechanism of Action 90 Assessment by Route of Administration 94 Assessment by Molecule Type 96 Drug Profiles 98 (betamethasone dipropionate + calcipotriene) - Drug Profile 98 (betamethasone valerate + calcipotriene) - Drug Profile 99 (halobetasol propionate + tazarotene) - Drug Profile 100 AbGn-168H - Drug Profile 101 adalimumab biosimilar - Drug Profile 102 adalimumab biosimilar - Drug Profile 103 adalimumab biosimilar - Drug Profile 105 adalimumab biosimilar - Drug Profile 106 adalimumab biosimilar - Drug Profile 107 adalimumab biosimilar - Drug Profile 108 adalimumab biosimilar - Drug Profile 109 adalimumab biosimilar - Drug Profile 110 adalimumab biosimilar - Drug Profile 111 adalimumab biosimilar - Drug Profile 112 adalimumab biosimilar - Drug Profile 113 adalimumab biosimilar - Drug Profile 114 adalimumab biosimilar - Drug Profile 116 adalimumab biosimilar - Drug Profile 117 adalimumab biosimilar - Drug Profile 118 adalimumab biosimilar - Drug Profile 119 adalimumab biosimilar - Drug Profile 120 AM-001 - Drug Profile 121 amiselimod hydrochloride - Drug Profile 122 AVX-001 - Drug Profile 124 baricitinib - Drug Profile 125 bimekizumab - Drug Profile 128 bleselumab - Drug Profile 129 BMS-986165 - Drug Profile 130 brodalumab - Drug Profile 131 BTX-1308 - Drug Profile 133 C-82 - Drug Profile 134 calcipotriene - Drug Profile 135 CC-90005 - Drug Profile 136 certolizumab pegol - Drug Profile 137 CJM-112 - Drug Profile 146 dalazatide - Drug Profile 147 DFD-01 - Drug Profile 149 DFD-06 - Drug Profile 150 dimethyl fumarate - Drug Profile 151 dimethyl fumarate - Drug Profile 152 DLX-105 - Drug Profile 153 DNX-114 - Drug Profile 155 etanercept - Drug Profile 156 etanercept biosimilar - Drug Profile 158 etanercept biosimilar - Drug Profile 159 etanercept biosimilar - Drug Profile 160 etanercept biosimilar - Drug Profile 161 etanercept biosimilar - Drug Profile 162 etanercept biosimilar - Drug Profile 164 etanercept biosimilar - Drug Profile 165 GK-664S - Drug Profile 166 GRMD-02 - Drug Profile 167 GSK-2831781 - Drug Profile 170 GSK-2981278 - Drug Profile 171 guselkumab - Drug Profile 172 IDP-122 - Drug Profile 174 IMO-8400 - Drug Profile 175 IMP-731 - Drug Profile 177 infliximab biosimilar - Drug Profile 178 infliximab biosimilar - Drug Profile 179 infliximab biosimilar - Drug Profile 181 infliximab biosimilar - Drug Profile 182 infliximab biosimilar - Drug Profile 183 INV-103 - Drug Profile 184 ixekizumab - Drug Profile 186 KD-025 - Drug Profile 188 KM-133 - Drug Profile 190 LEO-32731 - Drug Profile 192 LP-0113 - Drug Profile 193 M-7040 - Drug Profile 194 MC-201 - Drug Profile 195 namilumab - Drug Profile 196 pefcalcitol - Drug Profile 198 PF-06700841 - Drug Profile 200 PH-10 - Drug Profile 201 piclidenoson - Drug Profile 203 RA-18C3 - Drug Profile 205 remetinostat - Drug Profile 207 risankizumab - Drug Profile 209 RTU-1096 - Drug Profile 211 seletalisib - Drug Profile 212 tildrakizumab - Drug Profile 213 tofacitinib - Drug Profile 214 toreforant tartrate - Drug Profile 219 ustekinumab biosimilar - Drug Profile 221 ustekinumab biosimilar - Drug Profile 222 ustekinumab biosimilar - Drug Profile 223 ZPL-3893787 - Drug Profile 224 Plaque Psoriasis (Psoriasis Vulgaris) - Recent Pipeline Updates 225 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects 309 Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products 316 Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones 318 Featured News & Press Releases 318 Appendix 327 Methodology 327 Coverage 327 Secondary Research 327 Primary Research 327 Expert Panel Validation 327 Contact Us 327 Disclaimer 328
List of Tables
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2016 18 Number of Products under Development by Companies, H1 2016 20 Number of Products under Development by Companies, H1 2016 (Contd..1) 21 Number of Products under Development by Companies, H1 2016 (Contd..2) 22 Number of Products under Development by Companies, H1 2016 (Contd..3) 23 Comparative Analysis by Late Stage Development, H1 2016 24 Comparative Analysis by Clinical Stage Development, H1 2016 25 Comparative Analysis by Early Stage Development, H1 2016 26 Comparative Analysis by Unknown Stage Development, H1 2016 27 Products under Development by Companies, H1 2016 28 Products under Development by Companies, H1 2016 (Contd..1) 29 Products under Development by Companies, H1 2016 (Contd..2) 30 Products under Development by Companies, H1 2016 (Contd..3) 31 Products under Development by Companies, H1 2016 (Contd..4) 32 Products under Development by Companies, H1 2016 (Contd..5) 33 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by 3SBio Inc., H1 2016 34 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbGenomics International, Inc., H1 2016 35 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H1 2016 36 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H1 2016 37 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AstraZeneca Plc, H1 2016 38 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avexxin AS, H1 2016 39 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by BIOCAD, H1 2016 40 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H1 2016 41 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bionovis SA, H1 2016 42 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 43 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bristol-Myers Squibb Company, H1 2016 44 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Can-Fite BioPharma Ltd., H1 2016 45 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celgene Corporation, H1 2016 46 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cellceutix Corporation, H1 2016 47 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celltrion, Inc., H1 2016 48 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Clonz Biotech Private Limited, H1 2016 49 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Coherus BioSciences, Inc., H1 2016 50 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Delenex Therapeutics AG, H1 2016 51 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Eli Lilly and Company, H1 2016 52 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 53 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H1 2016 54 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Galectin Therapeutics, Inc., H1 2016 55 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co., Ltd., H1 2016 56 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by GlaxoSmithKline Plc, H1 2016 57 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 58 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Invion Limited, H1 2016 59 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H1 2016 60 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kadmon Corporation, LLC, H1 2016 61 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kineta, Inc., H1 2016 62 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 63 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H1 2016 64 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H1 2016 65 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mabion SA, H1 2016 66 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H1 2016 67 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 68 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016 69 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mycenax Biotech Inc., H1 2016 70 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Novartis AG, H1 2016 71 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Oncobiologics, Inc., H1 2016 72 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H1 2016 73 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H1 2016 74 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H1 2016 75 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016 76 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sandoz International GmbH, H1 2016 77 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H1 2016 78 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 79 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 80 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 81 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by TetraLogic Pharmaceuticals, H1 2016 82 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Therapeutic Proteins International, LLC, H1 2016 83 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by UCB S.A., H1 2016 84 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 85 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech USA, Inc., H1 2016 86 Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Ziarco Pharma Ltd, H1 2016 87 Assessment by Monotherapy Products, H1 2016 88 Assessment by Combination Products, H1 2016 89 Number of Products by Stage and Target, H1 2016 91 Number of Products by Stage and Mechanism of Action, H1 2016 97 Number of Products by Stage and Route of Administration, H1 2016 101 Number of Products by Stage and Molecule Type, H1 2016 103 Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics - Recent Pipeline Updates, H1 2016 231 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H1 2016 315 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..1), H1 2016 316 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..2), H1 2016 317 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..3), H1 2016 318 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..4), H1 2016 319 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..5), H1 2016 320 Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..6), H1 2016 321 Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H1 2016 322 Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products (Contd..1), H1 2016 323
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
